Table 1.
PARK loci/genes
| Gene | Locus | Inheritance | |
|---|---|---|---|
| PARK1/4 | SNCA | 4q22.1 | AD |
| PARK2 | PRKN | 6q26 | AR |
| PARK3 | _a | 2p13 | AD |
| PARK5 | UCHL1a | 4p13 | AD |
| PARK6 | PINK1 | 1p36.12 | AR |
| PARK7 | DJ1 | 1p36.23 | AR |
| PARK8 | LRRK2 | 12q12 | AD |
| PARK9 | ATP13A2 | 1p36.13 | AR |
| PARK10 | _a | 1p32 | AD |
| PARK11 | GIGYF2a | 2q37.1 | AD |
| PARK12 | _a | Xq21-q25 | X-linked |
| PARK13 | Omi/HtrA2a | 2p13.1 | AD |
| PARK14 | PLA2G6a | 22q13.1 | AR |
| PARK15 | FBXO7a | 22q12.3 | AR |
| PARK16 | _a | 1q32 | – |
| PARK17 | GAKb | 4p16 | – |
| PARK18 | HLA-DRAb | 6p21.3 | – |
SNCA = α-Synuclein; PRKN = parkin; UCHL1 = ubiquitin carboxyl-terminal esterase L1; PINK1 = PTEN-induced putative kinase 1; LRRK2 = leucine-rich repeat kinase 2; ATP13A2 = ATPase type 13A2; GIGYF2 = Grb10-interacting GYF protein 2; HtrA2 = HtrA serine peptidase 2; PLA2G6 = phospholipase A2, group 6; FBXO7 = F-box protein 7; GAK = cyclin G-associated kinase; HLA-DRA = major histocompatibility complex, class II, DR α; AD = autosomal dominant; AR = autosomal recessive.
a
Provisional loci/genes awaiting further confirmation.
b
Provisional loci/genes identified through the recent genome-wide association studies also awaiting further confirmation.